South Korea-based Daewoong Pharmaceutical has partnered with China-based Chime Biologics to develop and manufacture a dupilumab biosimilar candidate referencing Dupixent.

• Development: Chime Biologics will support the development and manufacturing of Daewoong Pharmaceutical’s dupilumab biosimilar candidate through its biosimilar development and commercialisation capabilities.
• Partnership: The agreement marks Daewoong Pharmaceutical’s entry into the biosimilar sector as part of its long-term growth strategy.
• Target area: The biosimilar candidate is aimed at the immunology market, including treatments for atopic dermatitis and other Type 2 inflammatory diseases.

This summary is based on a news article published by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.